Xylazine Outlasts the Overdose It Causes — And Policy Hasn’t Caught Up

In Worcester, Massachusetts, emergency doctors kept watching patients who should have been waking up. Naloxone had already reversed the fentanyl. Toxicology came back without anything else that should explain it. And still, hour after hour, the patients stayed under — breathing on their own, pulse steady, eyes closed, unresponsive to voice or a sternal rub, long past when a fentanyl-only overdose should have lifted.

Xylazine doesn’t play by the rules doctors learned from opioids, and the laws written to control it are still catching up.

Xylazine is a sedative made for horses and cattle — the kind veterinarians use to keep a thousand-pound animal still during a procedure — not a drug ever tested or approved for use in people. It works on a different set of nerve switches than opioids do: it’s what’s called an alpha-2 adrenergic agonist, meaning it locks onto receptors that control blood pressure, heart rate, and alertness, receptors that opioids never touch at all. Illicit chemists started cutting it into fentanyl earlier this decade, mostly to stretch supply and deepen a high, and it stuck around because it does something fentanyl alone doesn’t: it drags the sedation out for hours. People who use drugs and the harm reduction workers who serve them call it “tranq,” and the wounds it leaves — deep, slow-healing sores that can show up at sites nowhere near an injection — have become one of the signature injuries of this stretch of the drug supply.

A study published this year in Drug and Alcohol Dependence, led by Alex Krotulski, Michael Baumann, Brittany Chapman, Patricia Mae Martinez, John Broach, and Kavita Babu, gives the clearest human answer yet to why those Worcester patients stayed under so long. The researchers tracked 13 adult emergency department patients with confirmed xylazine and fentanyl exposure, five of whom also tested positive for medetomidine, a related veterinary sedative increasingly turning up alongside it. Initial blood levels averaged 47 nanograms per milliliter of xylazine, 14 ng/mL of fentanyl, 23 ng/mL of norfentanyl (what fentanyl breaks down into once the body starts metabolizing it), and 25 ng/mL of medetomidine. We’re relaying those figures via a research summary from the Partnership to End Addiction, since the original journal article wasn’t independently accessible at time of writing — worth saying plainly rather than dressing up as firsthand verification.

The half-life numbers are the real finding. In a subset of eight patients, researchers calculated half-life — the time it takes the body to clear half the drug from the bloodstream, a rough proxy for how long its effects should last. Xylazine’s half-life came out to 345 minutes, nearly six hours; fentanyl’s was 537 minutes. Veterinary and animal research had suggested xylazine should clear the body considerably faster than that. This is the first real human pharmacokinetic data on xylazine, and it means the drug hangs around in a person’s system substantially longer than the animal literature ever predicted — which lines up with what ER staff around the country have described anecdotally for years: patients who breathe fine after naloxone but stay unreachable far longer than a fentanyl-only overdose would explain.

This isn’t the first time the drug supply has quietly swapped in something worse than what people thought they’d bought. In the early 2010s, fentanyl itself was the adulterant — a cheap, extremely potent opioid cut into heroin batches by suppliers chasing a stronger, cheaper product, long before most people who used drugs, or even most doctors, understood what they were up against. It took years of unexplained overdose deaths before the pattern was named and emergency protocols caught up to the new chemistry. Xylazine is tracing the same arc now: a substance nobody using drugs asked for, absorbed into the supply for what it adds to potency and duration, discovered mostly through toxicology panels and ER charts rather than any warning label.

It took years of unexplained overdose deaths before the pattern was named and emergency protocols caught up to the new chemistry.

Xylazine sits inside a wider bucket public health researchers now track as novel-emerging substances — adulterants that spread through the fentanyl supply and cause documented harm well before anyone assigns them a name, a schedule, or a standard treatment protocol. The lag between contamination and clinical recognition is the actual hazard, not just the chemical itself.

If you use drugs, or you’re supporting someone who does, the wound care piece isn’t abstract. Xylazine-related sores don’t behave like ordinary injection wounds — they can show up away from injection sites entirely, they progress fast, and they respond badly to being left alone. Catching one early, with real wound care instead of waiting it out, is often the difference between a scar and an amputation. New York’s Senate Bill S2446 would fund exactly that kind of intervention: wound-care kits and xylazine test strips distributed through hospitals, treatment programs, shelters, and mobile health units, with a confidentiality rule barring facilities from recording who picked supplies up, and language that stops police from treating possession of a test strip as grounds for a stop or a search. It cleared committee in Albany this spring and is now sitting in Senate Finance. Whether test strips and wound kits are even legal to carry still depends on which state you’re standing in — the Network for Public Health Law’s 50-state survey of drug-checking equipment lays out how uneven that patchwork remains, more than three years into the xylazine crisis. Our harm reduction coverage has been tracking that unevenness state by state.

Scheduling tells a similar story of partial, scattered progress. Twenty-four states have introduced 58 separate legislative efforts to control xylazine, according to a count summarized by the National Governors Association, and most land on Schedule III — the tier that also covers ketamine and anabolic steroids, reflecting a recognized medical use (in veterinary medicine, not human medicine) alongside real potential for misuse. Ohio and Pennsylvania moved by executive and gubernatorial action back in 2023; West Virginia went a step further, to Schedule IV. What still doesn’t exist is a federal schedule. The Combating Illicit Xylazine Act has sat in Congress in one form or another since 2023, and a bipartisan coalition of roughly 40 state attorneys general sent a letter to congressional leadership on March 31, 2026, pressing lawmakers to finally pass it — arguing that without a federal schedule, the DEA can’t track manufacturing or cut off diversion at the source. The CDC still lists xylazine as federally unscheduled, a gap that state-by-state action can’t fully close, since supply chains don’t stop at state lines.

None of this changes what to do in the moment, and this part is not a hedge. If you witness an overdose and you don’t know what’s in the batch — increasingly, you can’t know — give naloxone anyway. It will not reverse xylazine’s sedative effects, because xylazine isn’t an opioid and naloxone only works on opioid receptors. But xylazine almost never travels alone; it’s riding along with fentanyl in nearly every documented case, and naloxone will still reverse that opioid component, restore breathing, and buy time. A person who’s received naloxone but still won’t wake up isn’t proof the naloxone failed. With xylazine in the picture, prolonged unresponsiveness after an otherwise-successful reversal is now something the data actually expects, not a signal to give up on. Stay with them, keep calling for help, and don’t mistake a slow wake-up for a failed one.

A tranquilizer built to keep a horse still on an operating table is now showing up on a Massachusetts ER’s toxicology panel, outlasting the tools built to reverse it. The bottleneck was never the chemistry — researchers can now measure exactly how long it sits in a person’s blood. The bottleneck is a test strip that’s still a legal risk to carry in some states, a wound care bill sitting in a finance committee, and a federal scheduling act that’s been waiting in Congress since before most of the patients it would protect ever heard the word xylazine.

The bottleneck was never the chemistry — researchers can now measure exactly how long it sits in a person’s blood.